In their letter, Reece and Hulse point to a lack of high quality comparative efficacy data for cannabis use in many conditions, in distinction to the efficacy data required for therapeutic goods already registered for these same indications. As outlined in our article,1 there are a number of “missing links” that need to be considered before Australia is confident that safe and effective cannabis can be available to people in need. Moreover, recent publications provide summaries of the evidence for and against its safety and efficacy.2,3
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.